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patients with high bleeding risk 3 months of an‑
ticoagulant treatment is suggested.2 Anticoagu‑
lant treatment was reported to prevent VTE recur‑
rence during its use and only to delay recurrence 
after its discontinuation.3 Most real ‑life patients 
discontinue anticoagulation a few months after 
the VTE event.4 Anticoagulation ‑related bleed‑
ing due to lifestyle (eg, alcohol abuse and smok‑
ing) may contribute to this phenomenon.5 It has 
been reported that the risk of VTE recurrence is 
INTRODUCTION Venous thromboembolism 
(VTE), comprising deep vein thrombosis (DVT) 
and pulmonary embolism (PE), is a common and 
potentially life ‑threatening disease.1 The risk of 
recurrence is higher after unprovoked VTE, and 
is estimated at about 10% at 1 year and 30% 
at 5 years.2 In patients with a first unprovoked 
VTE and low or moderate risk of bleeding, antico‑
agulant therapy longer than 3 months is recom‑
mended (no scheduled discontinuation), while in 
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INTRODUCTION The HERDOO2 rule can help identify patients in whom anticoagulation can be safely 
discontinued. Unfavorably altered fibrin clot properties predict recurrent venous thromboembolism (VTE).
OBJECTIVES We aimed to assess a possible association between fibrin clot properties and the HER‑
DOO2 score in women after unprovoked VTE.
PATIENTS AND METHODS Eighty women younger than 70 years after a first unprovoked VTE separately 
and combined with 32 women after hormone ‑related VTE were followed for a median of 48.5 months 
(interquartile range, 37.5–67 years). Plasma fibrin clot permeability (Ks), lysability, turbidity measurements, 
and thrombin generation were assessed 3 months after the index event in relation to the HERDOO2 score.
RESULTS Nineteen women (23.8%) with a HERDOO2 score equal to or higher than 2 were characterized 
by lower Ks
 
(–6.8%), indicating formation of more compact clots, impaired fibrinolysis as evidenced by 
a reduced maximum rate of D ‑dimer release from clots (D ‑Drate, by 6.8%), and prolonged clot lysis time 
(CLT, by 23.8%). No increased thrombin generation or differences in the remaining fibrin clot properties 
were observed. When combined with estrogen ‑related VTE, the same trends were observed. D ‑Drate and 
CLT correlated with the HERDOO2 score (r = –0.28, P = 0.01 and r = 0.35, P = 0.002, respectively) 
in 80 women with unprovoked VTE. Unfavorable clot phenotype, defined as Ks ≤6.55×10–9 cm2 and CLT 
>99.5 minutes, was associated with high risk of recurrence in the HERDOO2 rule (P = 0.02).
CONCLUSIONS We showed that middle ‑aged women after unprovoked VTE with high risk of recurrence 
based on the HERDOO2 rule are characterized by formation of denser fibrin clots and impaired fibrinolysis.
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(n = 2), and acute infection or exacerbated chron‑
ic inflammation (n = 3). Men who did not meet 
the above exclusion criteria (n = 155) were also 
excluded. Finally, we excluded women with VTE 
provoked by trauma, hospitalization, or preg‑
nancy/postpartum (n = 55). The current anal‑
ysis included 112 women with unprovoked and 
hormone ‑related VTE. The diagnosis of DVT was 
confirmed by a positive finding on color duplex 
ultrasound, and of PE, by positive results on high‑
‑resolution spiral computed tomography. Initial‑
ly, all patients were treated with unfractionated 
or low ‑molecular ‑weight heparin at therapeutic 
doses, and then vitamin K antagonists (VKAs) 
were continued for at least 3 months (hormone‑
‑related DVT) or 6 months (unprovoked DVT). 
Unprovoked VTE was defined as the absence of 
cancer history, surgery under general anesthe‑
sia, major trauma, plaster cast or hospitalization 
in the last month, and pregnancy or delivery in 
the last 3 months. Hormone ‑related VTE was 
defined as VTE associated with the use of oral 
contraceptives or hormone replacement therapy.
Women were classified into one of the two 
groups with a high (≥2 points) or low (0 or 1 
point) risk of recurrent VTE based on the HER‑
DOO2 rule.8,9
The university’s bioethical committee ap‑
proved the study, and all participants provided 
informed consent in accordance with the Decla‑
ration of Helsinki.
Follow ‑up Patients were followed on a 6 ‑month 
basis (a visit at the center or a telephone con‑
tact). The primary endpoint of the study was 
objectively documented symptomatic recurrent 
VTE. The end of follow ‑up was defined as the date 
of a recurrent thromboembolic event or death. 
The minimal follow ‑up for patients without re‑
current VTE was 30 months.
Laboratory investigations Fasting blood samples 
were drawn at 8 to 10 AM, after 12 to 15 weeks 
of anticoagulant treatment since DVT diagno‑
sis. Patients treated with VKAs were switched to 
low ‑molecular ‑weight heparin for 10 to 14 days, 
and blood samples were collected 16 to 24 hours 
after the last injection. Then, patients continued 
anticoagulation with VKAs. Blood cell count, 
lipid profile, glucose, creatinine, and INR were 
determined by routine laboratory techniques. 
Fibrinogen was measured by the Clauss meth‑
od, and C ‑reactive protein (CRP), by nephe‑
lometry (Siemens, Munich, Germany). D ‑di‑
mer, tissue plasminogen activator (tPA), and 
plasminogen activator inhibitor ‑1 (PAI ‑1) anti‑
gens were assayed (American Diagnostica Inc., 
Stamford, Connecticut, United States). Perme‑
ation of plasma fibrin clots in the assay involv‑
ing addition of tissue factor was assessed using 
a pressure ‑driven system and presented as Ks, as 
described previously.16 We recorded a lag phase 
before the start of fibrin polymerization initi‑
ated by adding a Tris buffer containing human 
1.75 ‑fold higher in men and 2 ‑fold higher in pa‑
tients with elevated D ‑dimer levels.2
It is suggested that anticoagulant treatment 
can be safely stopped if the risk of recurrent VTE 
is lower than 5% during a year since discontinu‑
ation.6 The prediction of recurrent VTE follow‑
ing discontinuation is still a challenge. Several 
strategies regarding anticoagulation withdraw‑
al after the first unprovoked VTE were proposed, 
including the Vienna Prediction Model, the Dash 
score, or the HERDOO2 rule.7,8 The latter iden‑
tifies women at low risk of recurrence (women 
meeting a maximum of 2 of the following criteria: 
hyperpigmentation, edema or redness [HER] in 
either leg, increased D ‑dimer levels ≥250 ng/ml; 
obesity with body mass index ≥30 kg/m2; or old‑
er age ≥65 years), in whom anticoagulants can 
be stopped after 5 to 7 months since an unpro‑
voked VTE event.8 In a prospective study, Rod‑
ger et al9 observed that the rate of recurrence 
after discontinuation of anticoagulant therapy 
was 3% per patient ‑year (95% CI, 1.8%–4.8%) 
in low ‑risk women (HERDOO2 score of 0 or 1) 
and 7.4% per patient ‑year (95% CI, 3%–15.2%) 
in high ‑risk women. D ‑dimer levels of 500 ng/ml 
or lower and peak thrombin generation of less 
than 400 nM measured after treatment discon‑
tinuation have been also proposed to identify pa‑
tients at low risk of recurrent VTE.2,8,10
Evidence indicates that formation of more 
compact clots, relatively resistant to lysis, me‑
diated by both environmental and genetic fac‑
tors, may predispose to VTE11 (particularly un‑
provoked VTE)12 and may have a prognostic value 
in VTE prediction.13,14 The postthrombotic syn‑
drome and associated recurrent VTE have been 
reported to be related with prothrombotic plasma 
clots.15 To our knowledge, it is unknown whether 
the HERDOO2 rule is associated with unfavor‑
able fibrin clot properties and increased throm‑
bin generation. For this reason, we sought to as‑
sess the association between the HERDOO2 rule 
and fibrin clot properties assessed 3 months af‑
ter the VTE event and to investigate whether this 
rule could be helpful in choosing patients with 
an increased risk of recurrent VTE in our cohort 
of women after unprovoked VTE.
PATIENTS AND METHODS We screened 368 con‑
secutive outpatients (age ≤70 years) after a first 
unprovoked VTE episode who were referred for 
further clinical evaluation, including the decision 
on extended anticoagulant therapy between Oc‑
tober 2008 to June 2010. The methodology and 
patient characteristics were described in our pre‑
vious report.13 We excluded patients with known 
malignancy (n = 12), chronic kidney disease stage 
4 or 5 (n = 4), severe thrombophilia, including 
antiphospholipid syndrome, antithrombin defi‑
ciency, and homozygous factor V Leiden or pro‑
thrombin 20210A mutations (n = 24), pregnancy 
(n = 1), international normalized ratio (INR) of 
more than 1.2 (n = 2), acute coronary syndrome 
or ischemic stroke within the previous 3 months 
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When women with unprovoked VTE and 
hormone ‑related VTE were analyzed together, 
the same trends were observed between high‑ 
and low ‑risk groups (n = 112; data not shown).
The HERDOO2 rule and fibrin clot properties Among 
women after unprovoked VTE (n = 80), those 
classified as high risk according to the HER‑
DOO2 rule had significantly lower Ks (by 6.8%), 
reduced D ‑Drate (6.8%), and prolonged CLT 
(23.8%) compared with the remaining patients 
(TABLE 1, FIGURE 1), also after adjustment for fibrin‑
ogen (except for Ks; P = 0.22). After inclusion of 
women with hormone ‑related VTE, the same 
trends were observed. Women treated with 
statins did not differ from the remaining pa‑
tients in fibrin clot properties except for short‑
er CLT (82.6 [16.5] min and 90.8 [17.1] min, re‑
spectively, P = 0.03).
D ‑Drate and CLT were correlated with the HER‑
DOO2 score in women after unprovoked VTE (r 
= –0.28, P = 0.01 and r = 0.35, P = 0.002, respec‑
tively). We observed a positive association be‑
tween the HERDOO2 score of 2 or higher and 
prothrombotic phenotype (P = 0.02) in women 
with unprovoked VTE, but the association was 
no longer observed after including women with 
hormone ‑related VTE in the analysis (P = 0.07).
There was no difference in fibrin clot prop‑
erties and thrombin generation between wom‑
en with and without 1 point for the HER com‑
ponent (TABLE 2). Patients with D ‑dimer levels 
of 250 ng/ml or higher (66.3%) had prolonged 
time to peak thrombin compared with those with 
the levels below 250 ng/ml (4.8 [4.3–5.3] min vs 
4.2 [3.9–5.3] min; P = 0.02). They also had re‑
duced D ‑Drate and prolonged CLT (TABLE 2). Obese 
patients (21.3%) had higher ΔAbs, lower D ‑Drate, 
and longer CLT compared with the remaining pa‑
tients (TABLE 2).
Follow ‑up Three women with unprovoked VTE 
and 1 woman with hormone ‑related VTE were 
lost to follow ‑up. All patients were followed for 
a median of 48.5 months (IQR, 37.5–67 months).
In 19 high ‑risk women after unprovoked VTE 
(23.75%), 10 recurrent VTE events occurred (1.15% 
recurrent VTE per patient ‑year; 95% CI, 0.44%–
1.86%). Among 61 low ‑risk women (76.25%), there 
were 21 recurrent VTE episodes during follow ‑up 
(0.73% recurrent VTE per patient ‑year; 95% CI, 
0.42%–1.04%). Women after unprovoked VTE 
with a HERDOO2 score of 2 or higher did not 
have an increased risk of recurrent VTE compared 
with the remaining patients (OR, 2.12; 95% CI, 
0.75–6.01; TABLE 3). The same was observed after 
the inclusion of patients with hormone ‑related 
VTE (OR, 2.26; 95% CI, 0.9–5.67).
The prothrombotic clot phenotype, defined 
as Ks ≤6.55×10
–9 cm2 and CLT >99.5 minutes, 
was associated with a higher risk of recurrent 
VTE separately for women after unprovoked VTE 
(OR, 5.33; 95% CI, 1.29–22.02) and after the in‑
clusion of hormone ‑related VTE women (OR, 
thrombin (Sigma ‑Aldrich, St. Louis, Missouri, 
United States) and CaCl
2
 to plasma samples, 
slope of the polymerization curve, and the max‑
imum absorbance at plateau.12,17 Two methods 
were implemented to assess the efficiency of clot 
lysis, as described previously.18,19 The calibrated 
automated thrombogram (CAT) was performed 
(Thrombinoscope, BV, Maastricht, the Nether‑
lands).20 Briefly, plasma samples were mixed 
with recombinant relipidated tissue factor and 
phospholipids. A  starting reagent contains 
CaCl
2 
and fluorogenic substrate. The Fluoroskan 
Ascent® microplate fluorometer (Thermo Fish‑
er Scientific, Vantaa, Finland) was used to read 
the fluorescence intensity. The peak thrombin, 
endogenous thrombin potential, and the time 
to thrombin peak were assessed. We determined 
factor V Leiden, prothrombin 20210A, as well 
as 2 additional mutations, FXIII Val34Leu and 
α fibrinogen Thr312Ala polymorphisms, as de‑
scribed previously.12
Statistical analysis Continuous variables were 
presented as mean (SD) or median (interquar‑
tile range [IQR]), while categorical and qualita‑
tive variables, as number (percentage). The nor‑
mality of variable distribution was checked with 
the Shapiro–Wilk test. The Fisher exact test, 
Spearman rank correlation test, Student t test, 
Welch t test, and Mann–Whitney test were used 
as appropriate. The univariate Cox proportional 
hazards models and logistic regression for risk 
factors for recurrent VTE were performed and 
expressed as hazard ratios (HRs) or the odds ra‑
tio (OR) with 95% CI. The association between a 
prothrombotic phenotype and a HERDOO2 score 
of 2 or higher was analyzed using the χ2 test. 
The level of significance for the 2 ‑sided tests was 
set below 0.05. All data management and anal‑
yses were performed using Statistica 13 (Stat‑
Soft Inc., Tulsa, Oklahoma, United States) and 
R package (R Core Team, 2016).
RESULTS A  total of 112  women, including 
80 women with unprovoked VTE (TABLE 1) and 
32  women with hormone ‑related VTE after 
a first VTE episode, were enrolled into the study. 
The mean (SD) age of patients was 44.8 (10.8) 
years.
The groups did not differ in baseline charac‑
teristics except for a higher proportion of DVT 
combined with PE in patients with unprovoked 
VTE (37.5% vs 9.4%, P <0.001). Women with 
a HERDOO2 score of 2 or higher were less com‑
monly treated with statins (TABLE 1).
High risk of recurrent VTE was observed in 
19 women (23.75%), and low risk, in 61 (76.25%). 
High ‑risk patients were characterized by higher 
body mass index (by 18%) and higher levels of 
glucose (8%), triglycerides (52.8%), CRP (58.3%), 
fibrinogen (10.7%), D ‑dimer (15.1%) (TABLE 1). 
Other routine laboratory tests, including tPA, 
PAI ‑1, peak thrombin, and endogenous thrombin 
potential, were similar in both groups.
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TABLE 1 Baseline characteristics of women after unprovoked venous thromboembolism depending on 
the HERDOO2 score (continued on the next page)








Age, y, mean (SD) 44.7 (12.1) 44.7 (14.1) 44.7 (11.6) 0.99
BMI, kg/m2, median (IQR) 26.2 (24.2–29.4) 30.2 (29.7–33) 25.6 (23.8–27) <0.001
Time of anticoagulation, mo, 
median (IQR)
12 (11–13.5) 13 (12–14) 12 (10–13) 0.17
Current smokers, n (%) 20 (25) 2 (10.5) 18 (30) 0.13
Family history of VTE, n (%) 11 (13.8) 2 (10.5) 9 (14.8) 0.64
Compression therapy, n (%) 54 (67.5) 16 (84.2) 38 (62.3) 0.07
Comorbidities, n (%)
Hypertension 26 (32.5) 7 (36.8) 19 (31.1) 0.64
Diabetes 1 (1.3) 0 (0) 1 (1.6) 0.57
Heart failure 1 (1.3) 0 (0) 1 (1.6) 0.57
Medications, n (%)
Aspirin 11 (13.8) 2 (10.5) 9 (14.8) 0.64
Sulodexide 6 (7.5) 1 (5.3) 5 (8.2) 0.67
ACEI 12 (15) 4 (21.1) 8 (13.1) 0.40
β ‑blocker 3 (3.8) 2 (10.5) 1 (1.6) 0.07
Statin 40 (50) 5 (26.3) 35 (57.4) 0.02
Laboratory parameters, median (IQR) (unless indicated otherwise)
Creatinine, µmol/l 69.4 (61–75.5) 68 (61–71) 70.0 (61–78) 0.6
Glucose, mmol/l, mean (SD) 5.1 (0.7) 5.4 (0.7) 5 (0.7) 0.02
Triglycerides, mmol/l 1.13 (0.73–1.61) 1.62 (0.7–2.4) 1.06 (0.76–1.44) 0.04
Total cholesterol, mmol/l 5.05 (4.22–5.65) 4.79 (4.33–5.37) 5.08 (4.2–5.78) 0.25
LDL cholesterol, mmol/l (SD) 3 (0.74) 2.94 (0.66) 3.01 (0.77) 0.69
HDL cholesterol, mmol/l 1.53 (1.24–1.74) 1.4 (1.19–1.78) 1.55 (1.28–1.72) 0.57
C‑reactive protein, mg/l 1.3 (0.8–2) 1.9 (1.2–2.5) 1.2 (0.8–1.8) 0.005
International normalized ratio 0.99 (0.9–1.04) 1 (0.95–1.03) 0.98 (0.9–1.05) 0.72
Fibrinogen, g/l 2.8 (2.4–3.6) 2.99 (2.6–4.55) 2.7 (2.4–3.4) 0.04
D ‑dimer, ng/ml 286.5 (240.5–337.5) 298 (260–451) 259 (232–322) 0.01
TPA, ng/ml 10 (7–11.7) 10.3 (7.8–11.9) 10 (7–11.6) 0.57
PAI ‑1, ng/ml 12.3 (9–16.9) 12.9 (9.1–16.7) 12.3 (9–16.9) 0.96
Peak thrombin, nM 243.6 (204–302) 279. 3 (219.4–305.4) 240 (201.6–299.6) 0.22
ETP, nM × min 1534.2 (230.2) 1581 (224.6) 1520 (232) 0.31
Time to thrombin peak, min 4.67 (4.21–5.33) 4.6 (4.2–6) 4.7 (4.2–5.3) 0.64
Genotyping, n (%)
Factor V Leiden 15 (18.7) 3 (15.8) 12 (19.7) 0.99
Prothrombin 20210A 4 (5) 1 (5.3) 3 (4.9) 0.99
Factor XIII Val34Leu 40 (50) 12 (63.2) 28 (45.9) 0.19
α ‑fibrinogen Thr312Ala 29 (36) 8 (42.1) 21 (34.4) 0.53
Fibrin clot features, median (IQR)
Ks, 10–9 cm2 7.40 (6.55–8.0) 6.9 (5.9–7.8) 7.4 (6.8–8.10) 0.05
Lag phase, s 41.5 (38.5–45) 40 (35–45) 42 (39–45) 0.27
ΔAbs 0.81 (0.76–0.86) 0.85 (0.79–0.9) 0.81 (0.75–0.85) 0.06
D ‑Dmax, mg/l 4.2 (3.7–4.4) 4.31 (3.7–4.59) 4.07 (3.67–4.39) 0.37
D ‑Drate, mg/l/min 0.071 (0.067–0.078) 0.068 (0.065–0.07) 0.073 (0.069–0.08) 0.001
CLT, min 86.5 (72–99.5) 99 (85–106) 80 (70–98) 0.005
SI conversion factors: to convert time to thrombin peak to seconds, multiply by 60; CLT to seconds, by 60; D ‑Drate 
to mg/l/s, divide by 60.
Abbreviations: ΔAbs, difference between maximum and minimum absorbance in the turbidimetric clotting assay; ACEI, 
angiotensin ‑converting enzyme inhibitor; BMI, body mass index; CLT, clot lysis time; D ‑Dmax, maximum D ‑dimer levels 
in the lysis assay; D ‑Drate, maximum rate of increase in D ‑dimer levels in the lysis assay; ETP, endogenous thrombin 
potential; HDL , high ‑density lipoprotein; HERDOO2, hyperpigmentation, edema or redness in either leg, increased 
D ‑dimer levels, obesity, or older age; IQR, interquartile range; Ks, fibrin clot permeability coefficient; LDL, low ‑density 
lipoprotein; PAI ‑1, plasminogen activator inhibitor ‑1; tPA, tissue plasminogen activator; VTE, venous thromboembolism
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using the HERDOO2 rule and an increased risk 
of VTE recurrence reported in several studies. 
We previously demonstrated that the prothrom‑
botic plasma clot phenotype might help identi‑
fy patients at higher risk of VTE.13,14 Similar, al‑
though less pronounced, alterations were detect‑
ed in the current analysis. However, we failed to 
show the predictive value of the HERDOO2 in our 
cohort of relatively young women. Nevertheless, 
the association cannot be excluded because of 
the wide ranges of CI values (separately in wom‑
en with unprovoked VTE and when analyzed to‑
gether with women with hormone ‑related VTE).
6.04; 95% CI, 1.94–18.8). Women with unpro‑
voked VTE compared with hormone ‑related VTE 
did not have an increased risk of VTE recurrenc‑
es (HR, 1.61; 95% CI, 0.74–3.51).
DISCUSSION In this study we showed that un‑
favorably altered fibrin clot properties, but not 
thrombin generation, occur in women after a first 
unprovoked VTE with a HERDOO2 score of 2 or 
higher. Our findings indicate that abnormal fi‑
brin clot properties, including increased clot den‑
sity and lysability, could at least partially explain 
the association between high scores calculated 
FIGURE 1 Fibrin clot permeability coefficient and clot lysis time (CLT) for patients after unprovoked venous thromboembolism classified as low (0 or 
1 point; n = 61) and high risk (≥2 points; n = 19) according to the HERDOO2 rule. Horizontal lines represent means in each group. 
Abbreviations: see TABLE 1




















TABLE 2 Comparison of plasma fibrin clot properties according to the components of the HERDOO2 rule among patients after unprovoked venous 
thromboembolism
HERDOO2 component Plasma fibrin clot properties
Ks, × 10–9 cm2 Lag phase, s ΔAbs D ‑Dmax, mg/l D ‑Drate, mg/l/min CLT, min
HER
Yes (n = 13) 7 (0.9) 41.6 (6.3) 0.79 (0.76–0.88) 4 (3.7–4.4) 0.072 (0.009) 92 (75–103)
No (n = 67) 7.3 (1.1) 42.1 (5.1) 0.82 (0.75–0.86) 4.2 (3.7–4.4) 0.072 (0.007) 86 (72–99)
P value 0.42 0.75 0.92 0.96 0.89 0.73
D ‑dimer, ng/ml
≥250 (n = 53) 7.1 (1.1) 41 (37–45) 0.82 (0.75–0.87) 4.2 (3.6–4.4) 0.071 (0.066–0.074) 92 (77–103)
<250 (n = 27) 7.5 (1.1) 43 (40–45) 0.81 (0.77–0.85) 4.3 (3.8–4.4) 0.076 (0.068–0.081) 75 (70–90)
P value 0.1 0.15 0.98 0.4 0.02 0.003
Obesity
Yes (n = 17) 6.9 (1.2) 40.5 (4.8) 0.85 (0.79–0.9) 4.3 (4.1–4.4) 0.069 (0.066–0.07) 96.2 (16)
No (n = 63) 7.4 (1.1) 42.5 (5.4) 0.81 (0.74–0.85) 4 (3.6–4.4) 0.072 (0.067–0.08) 84.1 (16.7)
P value 0.13 0.17 0.02 0.13 0.04 0.009
Data are presented as mean (SD) or median (interquartile range). 
No comparisons regarding age ≥65 years are shown due to a limited number of patients older than ≥65 years (n = 4).
SI conversion factors: see TABLE 1
Abbreviations: HER, hyperpigmentation, edema or redness in either leg; others see TABLE 1
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fibrinogen.23 This could partially explain why in 
our study the difference in Ks
 
was no longer ob‑
served after adjustment for fibrinogen, a main de‑
terminant of clot characteristics,24 when patients 
were divided according to the HERDOO2 rule. 
The current study provides additional evidence 
for prothrombotic alterations in obesity, includ‑
ing hypofibrinolysis.
The key finding of the present study is slightly 
lower Ks (by 6.8%) and markedly prolonged CLT 
(by 23.8%) observed in high ‑risk women after un‑
provoked VTE, which supports the concept that 
the prothrombotic fibrin clot phenotype has im‑
portant contribution to a prothrombotic state 
following VTE. Importantly, no evidence of in‑
creased thrombin generation using the CAT as‑
say was noted, indicating that another mechanism 
underlies changes in clot structure and function. 
Reduced D ‑Drate (by 6.8%) that was also observed 
in high ‑risk women and reflected impaired trans‑
port of tPA in fibrin networks and its slower deg‑
radation even at higher tPA concentrations con‑
firms that higher HERDOO2 scores are associat‑
ed with hypofibrinolysis. A similar abnormality 
has been reported to predispose to residual vein 
obstruction,25 which might increase the risk of 
DVT recurrence.
Patients characterized by a combination of risk 
factors of recurrent VTE could be predisposed to 
forming more compact plasma fibrin clots associ‑
ated with impaired susceptibility to lysis. The cor‑
relations between D ‑Drate, CLT and the HER‑
DOO2 score shown in our study could support 
the concept that the predictive value of the HER‑
DOO2 rule is partially driven by alterations in fi‑
brin clot properties. However, whether the same 
alterations can be seen in elderly women after un‑
provoked VTE remains to be established. In our 
cohort, women with high HERDOO2 scores were 
less commonly treated with statins. It has been 
reported that statins could improve fibrin clot 
properties17,26 and could have a beneficial effect 
on the risk of VTE recurrence.27,28 We observed 
faster fibrinolysis in women receiving statins, 
which supports the role of statins as modifiers 
of clot properties.
Unlike some other researchers,8,29 we did not 
classify hormone‑ or pregnancy ‑related VTE as 
unprovoked in this study, even if the risk of recur‑
rent VTE is increased in women with hormone‑
‑related VTE compared with those with VTE 
provoked by surgery or trauma.29 We found that 
women after VTE related to the use of oral con‑
traceptives or hormone replacement therapy did 
not differ in the risk of VTE recurrences com‑
pared with women after unprovoked VTE, which 
is in line with previous studies.30,31 However, sub‑
jects after VTE related to estrogen use had a low‑
er recurrence risk by 29% compared with non‑
users (adjusted HR, 0.71; 95% CI 0.58–0.88) in 
the study of 4170 women aged 15 to 64 years.32 
Importantly, in women with factor V Leiden mu‑
tation, discontinuation of oral contraceptives in‑
creased Ks and shortened CLT.
33
The components of the HERDOO2 rule, includ‑
ing postthrombotic syndrome, increased D ‑dimer, 
obesity, and older age, have been reported to be 
independent risk factors of recurrent VTE.2,8,21 In 
the previous study, we demonstrated that the oc‑
currence of postthrombotic syndrome is associ‑
ated with lower Ks, reduced D ‑Drate, and longer 
CLT,15 and all these parameters predicted recur‑
rent VTE.13,15 This could explain how the HER 
item could contribute to the association between 
prothrombotic phenotype and high risk according 
to the HERDOO2 rule. We did not observe HER‑
‑related differences in fibrin clot characteristics; 
however, patients who receive 1 point for HER 
tend to have lower Ks and longer CLT. Moreover, 
Rodger et al8 found that HER assessed after 5 to 
7 months of oral anticoagulant treatment was 
the strongest predictor of recurrent VTE. This ob‑
servation might refer to older women after un‑
provoked VTE, while the current study was per‑
formed in young and middle ‑aged women.
In our study obese women after unprovoked 
VTE were characterized by higher ΔAbs and lower 
D ‑Drate, while other fibrin clot features were simi‑
lar in obese and nonobese individuals. It has been 
observed that switching obese patients to low‑
‑fat diet resulted in shorter CLT but no change 
in Ks.
22 Recently, we reported that both high‑
er ΔAbs and reduced D ‑Drate were risk factors 
for recurrent VTE.13 It has been demonstrated 
that obese patients had higher concentrations of 
TABLE 3 Risk of venous thromboembolism recurrence according to 
the HERDOO2 components, HERDOO2 rule, and prothrombotic phenotype in women 
with unprovoked venous thromboembolism (n = 80)
HERDOO2 
component
VTE recurrence  
(n = 31)




No 26 (83.9) 41 (83.7) Reference
Yes 5 (16.1) 8 (16.3) 0.99 (0.30–3.34)
D ‑dimer ≥250 ng/ml, n (%)
No 6 (19.4) 21 (42.9) Reference
Yes 25 (80.6) 28 (57.1) 3.12 (1.09–8.98)
Obesity, n (%)
No 23 (74.2) 40 (81.6) Reference
Yes 8 (25.8) 9 (18.4) 1.55 (0.52–4.56)
Age ≥65 years, n (%)
No 29 (93.5) 49 (100) –
Yes 2 (6.5) 0 (0) –
HERDOO2 score, points, n (%)
0 or 1 21 (67.7) 40 (81.6) Reference
≥2 10 (32.3) 9 (18.4) 2.12 (0.75–6.01)
Prothrombotic phenotype
No 23 (74.2) 46 (93.9) Reference
Yes 8 (25.8) 3 (6.1) 5.33 (1.29–22.02)
HERDOO2 score ≥2 and prothrombotic phenotype, n (%)
No 27 (87.1) 47 (95.9) Reference
Yes 4 (12.9) 2 (4.1) 3.48 (0.6–20.28)
Abbreviations: OR, odds ratio; others, see TABLES 1 and 2
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We observed a lower rate of recurrent VTE in 
women compared with some previous reports 
on older patient populations.34 Moreover, we 
failed to find an increased risk of recurrent VTE 
in women with a HERDOO2 score of 2 or higher. 
This observation might result from a few discrep‑
ancies between studies. First, the number of in‑
dividuals in our study was limited. We assessed 
the HERDOO2 score after 12 to 15 weeks of anti‑
coagulant therapy, while the HERDOO2 rule was 
originally calculated after 5 to 7 months of anti‑
coagulation.9 Women in our high ‑risk group were 
younger than those reported by Rodger et al9 
(mean age, 44.7 years and 65.5 years, respec‑
tively). Low ‑risk women aged 50 years or older 
had a higher recurrence rate (5.7/100 patient‑
‑years vs 2/100 patient ‑years).9 Moreover, we 
measured D ‑dimer concentrations using a differ‑
ent assay from that used in the study by Rodger 
et al.9 Finally, unlike Rodger et al,9 we excluded 
patients with previous provoked VTE. Taken to‑
gether, the current study suggests that the val‑
ue of the HERDOO2 rule can be limited among 
women aged 65 years or younger, even if pro‑
thrombotic alterations can be detected in blood 
drawn from patients at high risk of VTE recur‑
rence using this rule. Still, long ‑term anticoag‑
ulant treatment in patients after unprovoked 
VTE is recommended,2 and the HERDOO2 rule 
is a clinical tool that can help identify young‑
er women who might benefit from long ‑term 
anticoagulation.35
Several study limitations should be considered. 
The number of study participants was limited, 
and we observed a low incidence rate of recurrent 
VTE events. Moreover, only patients suspected of 
VTE recurrence based on the signs and symptoms 
were evaluated by imaging, so asymptomatic VTE 
events might have been missed. We determined 
each variable at a single time point, so changes 
over time of some of them cannot be excluded. 
All patients after a first VTE episode discontin‑
ued VKA treatment during follow ‑up. It is unclear 
whether in patients after unprovoked VTE, treat‑
ment with non–vitamin K antagonist oral antico‑
agulants (instead of heparins and VKAs) as well 
as statin administration may impact the predic‑
tive value of the HERDOO2 rule as well as fibrin 
clot properties.28,29,36
In conclusion, we demonstrated that the pro‑
thrombotic clot phenotype is associated with 
a HERDOO2 score of 2 or higher in women after 
unprovoked VTE. This observation could provide 
a possible explanation for the predictive value of 
this scoring system in women after VTE; howev‑
er, the rule appears to have a limited usefulness 
in the prediction of recurrent VTE in middle‑
‑aged women. It is tempting to speculate that 
in this female population the assessment of clot 
density and lysability might be more useful than 
the HERDOO2 rule. However, large ‑scale stud‑
ies are needed to corroborate this hypothesis. 
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